The global japanese encephalitis (JE) vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Japanese encephalitis (JE) is a viral brain infection that is caused by the Japanese encephalitis virus (JEV) which is carried mostly by mosquitos and causes swelling of the brain. Additionally, it leads to significant mortality and neurological problems in infected individuals. The major factor for the growth of the market is the rising incidence of JE across the globe. 

According to the United Nations Children's Fund (UNICEF), JE is the leading cause of viral encephalitis which primarily affects children, in Asia and the Western Pacific. Additionally, it is endemic in 24 countries with an estimated 3 billion people at risk. Furthermore,  an estimated 70,000 clinical cases a year are caused due to JE out of which up to 30-50% of cases are at the risk of developing permanent neurologic or psychiatric sequelae with a fatality rate that can reach up to 30%, resulting in between 13,600 to 20,400 mortality. Moreover, 50% of JE cases in some countries occurrs in adults. Hence, the increasing incidence of JE is driving the demand for JE vaccines for treatment, which in turn is driving the growth of the market during the forecast period.

Some major players in the market include Sanofi SA, GlaxoSmithKline plc, and Novartis International AG, among others. Furthermore, government initiatives to prevent the disease is boosting the growth of the market. For inctamce, in October 2021, the Assam government launched an immunisation drive against Japanese encephalitis (JE) for the 15-65 age group while targeting to cover 40.17 lakh people.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Distribution Channel

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Sanofi SA, GlaxoSmithKline plc, and Novartis International AG, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Japanese Encephalitis (JE) Vaccine  Market Report by Segment

By Type

    • Inactivated Vaccines

    • Recombinant Vaccines

    • Live Attenuated Vaccines

By Distribution Channel

    • Hospital Pharmacies

    • Retail Pharmacies

    • E-Commerce

Global Japanese Encephalitis (JE) Vaccine  Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa